Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C
- 1 April 1994
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 19 (4) , 857-865
- https://doi.org/10.1002/hep.1840190409
Abstract
The human MxA protein is a new specific marker for type I interferon activity both in vitro and in vivo. In the study presented here this interferon-induced marker, as well as the 2′,5′-oligoadenylate synthetases, was measured in circulating mononuclear cells from 21 patients with acute hepatitis A, 20 patients with acute hepatitis B and 14 patients with acute hepatitis C for determination of the activiation of the interferon system in these viral diseases. In acute hepatitis A a strong expression (10 of 10 patients) of the MxA protein and the 2′,5′-oligoadenylate synthetase activity in peripheral-blood mononuclear cells was observed during the first 2 wk after onset of clinical symptoms. In this period the MxA protein concentrations reached levels similiar to those measured in patients treated with up to 5 × 106 IU interferon-α three times a week. Beyond wk 3, in eight of eight patients with hepatitis A no increased MxA protein levels were found. In contrast, peripheral-blood mononuclear cells from patients with acute hepatitis B contained either no measurable MxA protein or only slightly higher levels of the MxA protein, as did those of most patients (12 of 14) with acute hepatitis C. The MxA protein levels of both hepatitis B and C patients were significantly lower (p < 0.05) than those found in hepatitis A patients. Furthermore, sera from 6 of 10 patients with hepatitis A, but none of 10 patients with acute hepatitis B and C, contained measurable MxA protein. This serum MxA protein may originate from interferon-exposed and subsequently damaged liver cells. These results demonstrate that endogenous interferon is produced in large amounts during the first 2 wk of hepatitis A after onset of symptoms but not thereafter. In contrast, most patients with acute hepatitis B or C produce only minor amounts of interferon but do so for a prolonged period (> 6 wk). We conclude that hepatitis B virus and hepatitis C virus are poor interferon inducers and thus evade an important early defense mechanism against viral infection. (Hepatology 1994;19:857-865.)Keywords
This publication has 34 references indexed in Scilit:
- Possible prevention of chronic hepatitis B by early interferon therapyJournal of Hepatology, 1990
- Correlation of the Antiproliferative Effect and the Mx-Homologous Protein Induction by IFN in Patients with Malignant MelanomaJournal of Investigative Dermatology, 1990
- The interferon-induced Mx-homologous protein in people with symptomatic HIV-1 infectionAIDS, 1990
- Serology and Interferon Production during the Early Phase of Acute Hepatitis AThe Journal of Infectious Diseases, 1990
- Interferon-associated lymphocyte 2′,5′-oligoadenylate synthetase in acute and chronic viral hepatitisHepatology, 1989
- Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha InterferonNew England Journal of Medicine, 1986
- Lack Of In Vivo Activation of the Interferon System in Hbsag–Positive Chronic Active HepatitisHepatology, 1985
- Alpha Interferon for Induction of Remission in Hairy-Cell LeukemiaNew England Journal of Medicine, 1984
- Hepatitis A Infection in Chronic Carriers of Hepatitis B VirusHepatology, 1983
- Interferon therapy: Pharmacokinetic and pharmacological aspectsArchiv für die gesamte Virusforschung, 1981